Insulet (NASDAQ:PODD) Upgraded to Hold at Barclays

Key Points

• Barclays upgraded Insulet to “hold,” while the broader analyst consensus is also “hold,” with 13 buy ratings, 12 holds, and one sell rating. The average price target is $193.48.
• Insulet shares opened at $134.36, near the lower end of their 12-month range of $126.40 to $354.88, after several analysts recently reduced their price targets and ratings.
• The company reported a strong latest quarter, with EPS of $1.66 and revenue of $801.7 million, exceeding estimates and representing 23.5% year-over-year revenue growth.

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by equities researchers at Barclays to a "hold" rating in a report issued on Wednesday, Zacks reports.

A number of other research firms also recently issued reports on PODD. Benchmark cut their price target on Insulet from $250.00 to $185.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Raymond James Financial reiterated an "outperform" rating and issued a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Leerink Partners downgraded shares of Insulet from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. UBS Group cut their target price on shares of Insulet from $174.00 to $150.00 and set a "neutral" rating for the company in a research report on Thursday, August 6th. Finally, Oppenheimer cut shares of Insulet from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Thirteen analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Insulet presently has an average rating of "Hold" and an average price target of $193.48.

Insulet Stock Down 0.3%

Shares of NASDAQ PODD opened at $134.36 on Wednesday. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a market capitalization of $9.32 billion, a PE ratio of 25.11, a price-to-earnings-growth ratio of 1.06 and a beta of 1.11. The firm has a fifty day simple moving average of $142.95 and a two-hundred day simple moving average of $160.47. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. During the same period in the previous year, the firm posted $1.17 EPS. The business's revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts expect that Insulet will post 6.51 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Elevation Wealth Partners LLC grew its position in shares of Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 104 shares in the last quarter. MV Capital Management Inc. bought a new position in Insulet in the 4th quarter worth approximately $29,000. Continuum Advisory LLC bought a new position in Insulet in the 2nd quarter worth approximately $46,000. Sound Income Strategies LLC grew its holdings in Insulet by 4,620.0% during the 1st quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 231 shares in the last quarter. Finally, State of Wyoming raised its position in shares of Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock valued at $60,000 after buying an additional 73 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet's product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.